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Study Highlights 
1. WHAT IS CURRENT KNOWLEDGE 
• Epidemiological studies have shown an inverse association between Helicobacter pylori 
infection and risk of esophageal adenocarcinoma. 
• However, it remains unclear whether H. pylori is also inversely associated with the 
precursor lesion, Barrett’s esophagus, and whether H. pylori is associated with Barrett’s 
esophagus in the presence and/or absence of gastroesophageal reflux disease (GERD). 
2. WHAT IS NEW HERE 
• The findings from this large pooled analysis show that infection with H. pylori is 
associated with lower risk of Barrett’s esophagus, particularly the CagA positive strain. 
•  This lower risk is probably mediated by a decrease in GERD in infected patients, since 
the protective effect disappears in populations who have GERD symptoms. 
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ABSTRACT  
OBJECTIVES: Epidemiological studies of Helicobacter pylori infection and risk of Barrett’s 
esophagus (BE) have reported conflicting results. We examined the association between H. 
pylori infection and BE and sought to determine whether the association is mediated by 
gastroesophageal reflux disease (GERD) and to identify potential effect modifiers.  
METHODS: We used individual level data from 1308 patients with BE (cases), 1388 population-
based controls, and 1775 GERD controls in the Barrett’s and Esophageal Adenocarcinoma 
Consortium (BEACON). We estimated study-specific odds ratios (ORs) and 95% CIs using 
multivariable logistic regression models and obtained summary risk estimates using a random 
effects meta-analytic approach. We examined potential effect modification by waist-to-hip ratio 
(WHR), body mass index (BMI), and smoking status by conducting stratified analyses. 
RESULTS: For comparisons with population-based controls, H. pylori infection was inversely 
associated with the risk of BE (adjusted OR=0.44, 95% CI=0.36-0.55), with no evidence of 
between-study heterogeneity (I2=0%). A stronger inverse association between H. pylori and BE 
was observed among individuals with the CagA positive strain (P for interaction=0.017). We 
found no evidence of interaction between WHR, BMI, smoking status and H. pylori infection on 
the risk of BE. There was no association between H. pylori infection and BE for comparisons 
with GERD controls (OR=0.96, 95% CI=0.67-1.37; I2=48%).  
CONCLUSIONS: This study provides the strongest evidence yet that H. pylori infection is 
strongly inversely associated with BE. This effect is probably mediated by a decrease in GERD 
in infected patients, since the protective effect disappears in patients with GERD symptoms.
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INTRODUCTION 
In the United States, 16,940 new cases of esophageal cancer and 15,690 deaths from 
esophageal cancer are expected to occur in 2017.1 While recent decades have witnessed a 
decline in the incidence of squamous cell carcinoma of the esophagus,2 a rising trend of 
esophageal adenocarcinoma (EAC) incidence has been observed in many developed 
countries.3 In the United States, the annual incidence of EAC has increased 9-fold since the 
early 1970s.4  
 
Barrett’s esophagus (BE), a condition in which the normal squamous mucosa of the esophagus 
is replaced by columnar intestinal epithelium, is the precursor lesion for EAC.5 Patients with BE 
have 10- to 55-fold higher risk of EAC than the general population.6 Since BE is usually 
asymptomatic and remains clinically undetected, population-based studies have estimated a 
prevalence of 1.3-1.6% among general population,7,8 while clinic-based studies have estimated 
prevalence of 18.2% among patients undergoing endoscopy.9  
 
Assessment of risk factors for BE allows for better understanding of disease pathophysiology 
and identification of new opportunities for disease prevention. Population-based case-control 
studies initiated in the past two decades have thus far consistently identified frequent symptoms 
of gastroesophageal reflux disease (GERD),10 obesity,11 and possibly smoking12 as risk factors 
for BE. A potential protective factor for BE is infection with Helicobacter pylori. While H. pylori, 
especially the CagA positive (cytotoxin-associated gene product A-positive) strain, is a known 
strong risk factor for non-cardia gastric cancer  (potentially accounting for 90% of cases 
worldwide each year),13 the infection could decrease gastric acid production and subsequently 
reduce the likelihood of developing GERD, a major risk factor for BE.14 However, its role in 
reflux-induced esophageal injury and the effect of H. pylori eradication on GERD and reflux 
esophagitis continues to be debated.15 A meta-analysis of 49 observational studies examining 
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the association between H. pylori infection and the risk of BE published through 2010 found an 
inverse association, but with considerable between-study heterogeneity16 potentially from choice 
of control group (e.g., population-based vs. clinical controls) and BE case definition (e.g., with 
and without intestinal metaplasia, or incident vs. prevalent cases). While population controls are 
sampled from underlying population where cases arose and are asymptomatic, clinical controls 
represent a symptomatic population undergoing endoscopy and are the ideal comparison group 
for assessing whether an association with BE is mediated by GERD. Furthermore, the small 
size of these individual studies has also limited the precision of resulting estimates of 
association and few studies had data on CagA positivity status. Most studies were unable to 
adequately control for confounding and it is unknown to what extent these associations vary by 
population using harmonized adjusted models. Finally, investigations of whether these 
associations differ with respect to known risk factors for BE (e.g., obesity and cigarette smoking) 
have been limited due to small numbers upon stratification. 
 
To better understand this relationship, we assessed whether H. pylori infection is associated 
with the risk of BE by pooling, harmonizing, and analyzing individual-level participant data from 
six case-control studies. We also sought to determine whether or not the association of H. pylori 
infection with BE is mediated by GERD.
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METHODS 
Study population 
We analyzed individual-level participant data from the following six case-control studies in the 
international Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON, 
http://beacon.tlvnet.net/) that had available data on H. pylori infection status: the Houston 
Barrett’s Esophagus study (based at the Michael E. DeBakey VA Medical Center at Houston, 
TX; hereafter “Houston”);17 the Factors Influencing the Barrett’s/Adenocarcinoma Relationship 
study (based in Ireland; “FINBAR”);18 the Epidemiology and Incidence of Barrett’s Esophagus 
study (based in the Kaiser Permanente Northern California population; “KPNC”); 19 The Newly 
Diagnosed Barrett’s Esophagus Study (based at the University of Michigan and Ann Arbor 
Veterans Affairs Medical Center at Ann Arbor, MI; “NDB”);9 the Study of Digestive Health (based 
in Brisbane, Australia; “SDH”);20 and the Epidemiologic Case-Control Study of Barrett’s 
Esophagus (Chapel Hill, NC; “UNC”). The NDB study included only males (cases and controls) 9 
and the UNC study only included BE cases and GERD controls.20 The Institutional Review 
Boards or Research Ethics Committees of each institution approved the acquisition and pooling 
of data for the present analysis. Participants provided written informed consent to take part in 
the studies. 
 
In all studies, BE cases were persons with endoscopic evidence of columnar mucosa in the 
tubular esophagus and specialized intestinal metaplasia in an esophageal biopsy. We 
compared cases of BE with population-based controls, representing the underlying source 
population from which cases arose, and separately with GERD controls, representing the 
population undergoing endoscopy from which cases are diagnosed. GERD controls were 
participants who either were found to have erosive esophagitis on endoscopy or carried a 
clinician's diagnosis of GERD. Study-specific definitions for cases and controls are detailed in 
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Supplementary Table 1. Owing to low numbers of cases from other ethnic groups, we 
restricted our analyses to non-Hispanic white study participants.  
 
Study variables 
The main exposure was H. pylori infection status (negative vs. positive), which was determined 
at each study center using assays blinded to case-control status running in mixed batches of 
cases and controls. The ELISAs applied in the individual studies has been validated in other 
ethnic groups.21–23 Cases and controls from FINBAR, KPNC and NDB studies were also tested 
for antibodies to the H. pylori CagA protein.  
 
Potential confounding variables were available from all studies as part of a core dataset and 
were previously harmonized by the BEACON coordinating center.12,24–27 Variables selected a 
priori as adjustment factors included age (<50, 50-<60, 60-<70, ≥70 years), sex (except for NDB 
which included only males), highest level of education (school only, tech/diploma, university), 
cigarette smoking status (never, former, current), and body mass index (BMI; <25, 25-29.9, ≥30 
kg/m2). In a subset of studies, we also pooled and harmonized data on patient’s waist and hip 
measurements. Among participants with relevant data, a sensitivity analysis was also conducted 
to replace BMI in the model with waist-to-hip ratio (WHR) in quartile categorization to adjust for 
the effect of abdominal obesity instead of overall obesity. 
 
Statistical analysis 
Our primary analyses compared BE cases with population-based controls. We assessed the 
association between H. pylori infection and BE using a two-stage analytic approach.28 In the first 
stage, we used unconditional logistic regression models to estimate study-specific odds ratios 
(ORs) and 95% confidence intervals (CIs). In the second stage, the study-specific ORs were 
pooled using random-effects meta-analytic models to generate a summary OR. We used the 
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inconsistency index, I2, and corresponding p-value to assess heterogeneity between studies.29 
The I2 statistic estimates the percentage of total variation across studies due to heterogeneity. 
An I2 statistic of 0% indicates no heterogeneity that cannot be attributed to chance, whereas 
larger values indicate increasing heterogeneity beyond chance.29 We explored possible 
heterogeneity of the effect of H. pylori infection on risk of BE through analyses stratified by 
cigarette smoking status, BMI, and WHR (< median vs. ≥ median; median determined 
separately for each study). Potential interactions were assessed by fitting the interaction term 
between H. pylori infection status and the stratified variable into the model. Likelihood ratio tests 
of nested models with and without the interaction term were performed. To evaluate whether the 
virulent strain types of H. pylori could impact the effect of H. pylori on risk of BE, we further 
divided subjects into three groups: negative for H. pylori infection (reference group), positive for 
H. pylori infection with negative CagA antibody status; and positive for H. pylori infection with 
positive CagA antibody status. Finally, because the presence of H. pylori is thought to decrease 
gastric acid production and subsequently reduce the likelihood of developing GERD, we 
evaluated whether the association between H. pylori infection and BE was potentially mediated 
by GERD by comparing BE cases with GERD controls. To further verify an indirect pathway 
from H. pylori to BE through GERD, we also examined the association between H. pylori and 
GERD by comparing population-based controls with GERD controls. All analyses were 
conducted using SAS 9.4 (SAS Inc., Cary, NC, USA) and Cochrane review manager 5.3 
(Cochrane, London, UK). Statistical significance was determined at α = 0.05, and all p-values 
for statistical significance were two-sided.
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RESULTS 
We included data from 1308 BE cases, 1388 population-based controls and 1775 GERD 
controls. Across the six studies, 29.6% of population-based controls were H. pylori positive, 
while 17.2% of BE cases were H. pylori positive. However, the prevalence of H. pylori positive 
among controls (and cases) varied considerably across the six studies (Table 1). For example, 
prevalence of H. pylori positivity in population-based controls ranged from 18.9% in SDH to 
62.1% in FINBAR; in GERD controls, from in 4.4% in UNC to 42.4% in FINBAR; in BE cases, 
from 5.2% in UNC to 43.3% in FINBAR. 
 
In comparisons with population-based controls, we found an inverse association between H. 
pylori infection and BE. In the unadjusted analysis, infection with H. pylori was associated with 
50% lower odds of BE (summary OR=0.50, 95% CI=0.41-0.61, I2=0%, p=0.88). In models 
adjusted for age, sex, education, smoking status and BMI, H. pylori infection remained strongly 
inversely associated with BE (summary OR=0.44, 95% CI=0.36-0.55; I2=0%, p=0.63) (Figure 
1). As evidenced by the I2 statistics, no heterogeneity was observed across the included studies. 
Sensitivity analysis showed no alteration of associations after replacing BMI in the model with 
WHR (summary OR=0.45, 95% CI=0.36-0.56; I2=0%, p=0.52) (Supplementary Figure 1).  
 
We examined the association between H. pylori and BE within strata of known risk factors for 
BE (Table 2). We found consistently that H. pylori infection was inversely associated with BE 
across strata of smoking status (p-interaction=0.867) and WHR (p-interaction=0.684). We found 
some evidence for a stronger inverse association with H. pylori infection among persons with 
normal BMI (summary OR=0.27, 95% CI=0.13-0.56) than among overweight (summary 
OR=0.51, 95% CI=0.36-0.71) or obese (summary OR=0.47, 95% CI=0.33-0.80) persons, 
though the interaction term for H. pylori and BMI was not statistically significant (p-
interaction=0.20).  
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Further analysis was conducted to examine whether the inverse association differed by CagA 
(+/-) virulent strains of H. pylori infection (Table 3). By using the meta-analytical approach 
based on three studies (FINBAR, KPNC and NDB) with available CagA status information, the 
inverse association was somewhat stronger among subjects with CagA positive strain 
(summary OR=0.33, 95%CI=0.21-0.53) than those without (summary OR=0.56, 95%CI=0.38-
0.82, p-interaction=0.017). 
 
Finally, we examined for mediation by GERD by comparing BE cases with GERD controls. In 
the adjusted model, we found no association between H. pylori infection and the odds of BE 
(summary OR=0.96, 95% CI=0.67-1.37, I2=48%, p=0.10) (Figure 2). The existence of an 
indirect pathway from H. pylori infection to BE through GERD was further corroborated by the 
finding that H. pylori infection was strongly inversely associated with odds of GERD for 
comparisons of GERD controls with population-based control (summary OR=0.52, 95% 
CI=0.35-0.78, I2=69%, p=0.02) (Figure 3).
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DISCUSSION 
In this large pooled analysis of individual-level participant data from six well-characterized case-
control studies in BEACON, we found that H. pylori infection was associated with over 50% 
lower odds of BE. The magnitude of the inverse association was consistent across the included 
studies. In the stratified analyses, H. pylori infection was associated with lower odds of BE in all 
population sub-groups. However, we found no association between H. pylori infection and BE 
for comparisons with GERD controls, consistent with the hypothesis that the association 
between H. pylori infection and BE is mediated by GERD. Moreover, infection with more virulent 
strains provides increased protection against BE. While H. pylori infection decreases the risk of 
GERD in infected individuals, once a patient has GERD, there is no protection from BE 
associated with H. pylori.   
 
Our understanding of the relationship between H. pylori infection and BE has been hampered by 
conflicting results from studies often too small to adequately address the issue and of varying 
design. While some studies reported lower risk of BE associated with H. pylori infection (using 
population-based controls,19,30 endoscopy-negative controls,17,31 or GERD controls32,33), there 
was no association in other studies.34,35 The current analysis of individual-level participant data 
from studies participating in BEACON is much larger than any of these previous studies, and 
this larger sample size provided for greater statistical power and precision of risk estimates. 
Furthermore, the use of pooled and harmonized individual-level participant data provided more 
comparable statistical estimates than standard meta-analysis, which pool published ORs that 
differ in their variable definitions and the confounders included. In addition, the availability of 
both population-based controls and GERD controls allowed for comparisons with the underlying 
source population from which cases arose and the population undergoing endoscopy from 
which cases are diagnosed. Importantly, this also allowed us to examine whether H. pylori is 
associated with BE in the presence and/or absence of GERD; this is an important clinical 
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question. Therefore, the results of this analysis are the strongest available data to date 
regarding the association between H. pylori and BE. 
 
BE is the recognized precursor lesion of EAC and, if H. pylori infection was association with risk 
of BE, one can expect to observe an association between H. pylori infection and EAC as well. 
The results from population-based studies do provide strong evidence for an inverse association 
between H. pylori infection and EAC.18 Given the concordance of these data, associations 
between H. pylori infection and BE, as well as H. pylori infection and EAC, are likely to be real. 
The current results also provide strong evidence that H. pylori infection is associated with the 
risk of BE rather than risk of neoplastic progression in BE patients. In particular, we showed that 
H. pylori infection was strongly inversely associated with the risk of GERD. For symptomatic 
patients, there was no association between H. pylori infection and the risk of BE. Thus, the 
emphasis should be on managing GERD in these patients and not minimizing treatment efforts 
in H. pylori. 
 
Our study has several notable strengths. First, the consortium approach enabled generation of 
the largest reported cohort of participants with BE to date, upon which risk factor analysis has 
been performed. With over 1300 cases of BE, we had greater power to detect associations, if 
present, and report more precise estimates of association with H. pylori infection than in any 
previous study. Furthermore, the large size of the pooled database enabled greater sample size 
and statistical power for stratified analyses and the assessment of potential interactions. 
Second, since BEACON applied standardized protocols in harmonizing data and deriving 
variables standardized across studies, using individual-level participant data allows for many 
benefits over meta-analysis of published estimates, including building consistent statistical 
models across studies and studying novel questions. Third, we found little evidence of between 
study heterogeneity, and the wide distribution of H. pylori prevalence across studies suggests 
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our findings are generalizable to most settings. Fourth, the availability of both population-based 
controls and GERD controls allowed us to postulate where H. pylori infection might be active in 
the pathogenesis of BE. This is important because it is feasible that a significant proportion of 
the population-based control group might unknowingly have BE, although such misclassification 
would bias results toward the null. 
 
Our study also has a number of limitations. First, observational studies are subject to bias. 
Although analyses of multiple variables provided little evidence of confounding, we cannot 
exclude incomplete control of confounding. Further, our results may be due to reverse causation 
whereby BE patients may had been previously treated for H. pylori infection in the more distant 
past, thereby decreasing their antibody titers. Second, the measurements of CagA status were 
only limited in three studies, decreasing the precision of these estimates, and ruling out the 
possibility of stratified analyses. Third, most of the six studies included a mix of patients with 
newly diagnosed and prevalent diagnoses of BE, which could have biased the results 
unpredictably. Fourth, the absence of information on presence, distribution or severity of 
gastritis or gastric atrophy meant that we could not examine this factor as possible explanation. 
The Houston study previously found extent of gastritis as a possible explanation. 
 
In summary, this pooled analysis found evidence for an inverse association between H. pylori 
infection and the odds of BE, particularly the CagA positive strain. However, the association was 
mediated by GERD. H. pylori infection is not associated with BE among persons with GERD. 
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Figure Legend 
 
Figure 1. Forest plot for the association between H. pylori infection and risk of Barrett’s 
esophagus, compared with population-based controls. Odds ratios adjusted for age (<50, 50-59, 
60-69, ≥70 years), sex (except NDB, all male), education (school only, tech/diploma, university), 
smoking status (never, former, current), and body mass index (<25, 25-29.3, ≥30 kg/m2). 
 
Figure 2. Forest plot for the association between H. pylori infection and risk of Barrett’s 
esophagus, compared with GERD controls. Odds ratios adjusted for age (<50, 50-59, 60-69, 
≥70 years), sex (except NDB, all male), education (school only, tech/diploma, university), 
smoking status (never, former, current), and body mass index (<25, 25-29.3, ≥30 kg/m2). 
 
Figure 3. Forest plot for the association between H. pylori infection and risk of GERD, 
compared with population-based controls. Odds ratios adjusted for age (<50, 50-59, 60-69, ≥70 
years), sex (except NDB, all male), education (school only, tech/diploma, university), smoking 
status (never, former, current), and body mass index (<25, 25-29.3, ≥30 kg/m2). 
 
Supplementary Figure 1. Forest plot for the association between H. pylori infection and odds 
of Barrett’s esophagus, compared with population-based controls. Odds ratios adjusted for 
waist-to-hip ratio, compared with population-based controls. Odds ratios adjusted for age (<50, 
50-59, 60-69, ≥70 years), sex (except NDB, all male), education (school only, tech/diploma, 
university), smoking status (never, former, current), and waist-to-hip ratio (quartiles).
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Table 1. Characteristics of population-based controls, GERD controls and cases 
of Barrett’s esophagus by study 
 
Characteristics Population-based controls  
GERD  
controls 
BE  
cases 
Houston, n 278 857 289 
  Age, mean (SD) 62.7 (6.3) 60.4 (8.7) 61.6 (7.4) 
  Male, n (%) 273 (98.2) 778 (90.8) 282 (97.6) 
  Body mass index, mean (SD) 31.2 (6.3) 30.1 (6.0) 30.2 (5.5) 
  Current smoker, n (%) 66 (25.6) 235 (28.8) 86 (31.1) 
  H. pylori positive, n (%) 77 (27.7) 204 (23.8) 53 (18.3) 
FINBAR, n 253 229 215 
  Age, mean (SD) 62.7 (12.8) 61.3 (11.4) 62.1 (11.9) 
  Male, n (%) 214 (84.6) 188 (82.1) 180 (83.7) 
  Body mass index, mean (SD) 27.8 (3.9) 29.2 (4.0) 27.9 (4.3) 
  Current smoker, n (%) 46 (18.6) 50 (22.1) 51 (23.8) 
  H. pylori positive, n (%) 157 (62.1) 97 (42.4) 93 (43.3) 
KPNC, n 248 241 254 
  Age, mean (SD) 62.1 (10.1) 62.1 (10.4) 62.2 (10.8) 
  Male, n (%) 168 (67.7) 166 (68.9) 190 (74.8) 
  Body mass index, mean (SD) 29.5 (5.7) 29.0 (4.7) 29.4 (5.4) 
  Current smoker, n (%) 31 (12.5) 23 (9.5) 34  (13.4) 
  H. pylori positive, n (%) 52 (21.0) 18 (7.5) 28 (11.0) 
NDB, n 249 178 133 
  Age, mean (SD) 59.7 (6.9) 57.1 (6.1) 61.3 (6.9) 
  Male, n (%) 249 (100) 178 (100) 133 (100) 
  Body mass index, mean (SD) 30.1 (5.8) 29.9 (5.5) 30.5 (5.0) 
  Current smoker, n (%) 35 (14.1) 20 (11.3) 37 (27.8) 
  H. pylori positive, n (%) 57 (22.9) 25 (14.0) 18 (13.5) 
SDH, n 360 0 283 
  Age, mean (SD) 59.8 (10.7) - 60.0 (11.4) 
  Male, n (%) 233 (64.7) - 201 (71.0) 
  Body mass index, mean (SD) 27.1 (4.8) - 27.6 (4.7) 
  Current smoker, n (%) 39 (10.8) - 50 (17.7) 
  H. pylori positive, n (%) 68 (18.9) - 26 (9.2) 
UNC, n 0 270 134 
  Age, mean (SD) - 50.1 (14.2) 55.5 (10.6) 
  Male, n (%) - 114 (42.2) 89 (66.4) 
  Body mass index, mean (SD) - 27.9 (6.0) 28.8 (6.0) 
  Current smoker, n (%) - 40 (14.8) 20 (14.9) 
  H. pylori positive, n (%) - 12 (4.4) 7 (5.2) 
NOTE: Houston, the Houston Barrett’s Esophagus study; FINBAR, the Factors Influencing the 
Barrett’s/Adenocarcinoma   Relationship study (Ireland); KPNC, the Epidemiology and Incidence of Barrett’s 
Esophagus study (Kaiser Permanente, Northern California); NDB, The Newly Diagnosed Barrett’s Esophagus 
Study (University of Michigan and Ann Arbor Veterans Affairs Medical Center, Michigan); SDH, the Study of 
Digestive Health (Brisbane, Australia); and UNC, the Epidemiologic Case-Control Study of Barrett’s 
Esophagus (Chapel Hill, North Carolina). Participants with missing data were excluded from %s. 
 
21 
 
Table 2. ORs and 95% CIs for the association between H. pylori infection and odds of 
Barrett’s esophagus, compared with population-based controls, stratified by smoking 
status, body mass index and waist-to-hip ratio 
Strata 
BE /  
Population-based  
controls 
OR (95% CI)a OR (95% CI)b 
Smoking status    
  Never smoker 394/557 0.47 (0.32-0.69) (I2=0%, p=0.81) 
0.41 (0.27-0.62) 
(I2=0%, p=0.76) 
  Former smoker 611/588 0.51 (0.38-0.68) (I2=0%, p=0.93) 
0.46 (0.34-0.63) 
(I2=0%, p=0.90) 
  Current smoker 278/217 0.41 (0.26-0.64) (I2=0%, p=0.81) 
0.36 (0.21-0.59) 
(I2=0%, p=0.57) 
Body mass index    
  BMI <25 kg/m2 282/322 0.40 (0.23-0.68) (I2=21%, p=0.28) 
0.27 (0.13-0.56) 
(I2=43%, p=0.13) 
  BMI 25-29.9 kg/m2 528/579 0.57 (0.41-0.80) (I2=14%, p=0.33) 
0.51 (0.36-0.71) 
(I2=0%, p=0.42) 
  BMI ≥30 kg/m2 487/475 0.50 (0.36-0.71) (I2=0%, p=0.51) 
0.47 (0.33-0.80) 
(I2=0%, p=0.54) 
Waist-to-hip ratio    
  Waist-to-hip ratio <median 477/697 0.50 (0.37-0.67) (I2=0%, p=0.62) 
0.43 (0.31-0.60) 
(I2=0%, p=0.56) 
  Waist-to-hip ratio ≥median 606/646 0.52 (0.39-0.69) (I2=0%, p=0.44) 
0.48 (0.35-0.67) 
(I2=8%, p=0.36) 
CI, confidence interval; OR, odds ratio. 
a Unadjusted model. 
b Adjusted for age (<50, 50-59, 60-69, ≥70 years), sex (except NDB, all male), education (school only, 
tech/diploma, university), smoking status (except for when stratified by smoking status; never, former, current), 
and body mass index (except when stratified by BMI; <25, 25-29.3, ≥30 kg/m2). 
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Table 3. ORs and 95% CIs for the association between H. pylori infection and odds of 
Barrett’s esophagus, compared with population-based controls 
H. pylori antibody 
status 
CagA antibody 
status 
BE /  
Population-based controls OR (95% CI)a 
FINBAR    
  Negative   Negative 122/96 1.00 (ref.) 
  Positive   Negative 15/20 0.58 (0.28-1.22) 
   Positive 78/137 0.40 (0.26-0.60) 
KPNC    
  Negative   Negative 226/196 1.00 (ref.) 
  Positive   Negative 26/38 0.51 (0.29-0.89) 
   Positive 2/14 0.13 (0.03-0.59) 
NDB    
  Negative   Negative 115/192 1.00 (ref.) 
  Positive   Negative 13/28 0.63 (0.30-1.32) 
   Positive 5/29 0.26 (0.10-0.73) 
Overall    
  Negative   Negative 463/484 1.00 (ref.) 
  Positive   Negative 54/86 0.56 (0.38-0.82) 
   (I2=0%, p=0.89) 
   Positive 85/180 0.33 (0.21-0.53) 
   (I2=11%, p=0.33) 
CagA, cytotoxin-associated gene product A 
a Adjusted for age (<50, 50-59, 60-69, ≥70 years), sex (except NDB, all male), education (school only, 
tech/diploma, university), smoking status (never, former, current), and body mass index (<25, 25-29.3, ≥30 
kg/m2). 
 
 
